← Browse by Condition
Medical Condition

myasthenia gravis

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for myasthenia gravis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myasthenia gravis Clinical Trials

How many clinical trials are currently recruiting for myasthenia gravis?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for myasthenia gravis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myasthenia gravis?
myasthenia gravis research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myasthenia gravis clinical trial?
Eligibility criteria for myasthenia gravis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
2
Phase 3
1
Top Sponsors
Huashan Hospital 3 trials
TG Therapeutics, Inc. 1 trial
Kyverna Therapeutics 1 trial
Institut de Myologie, France 1 trial

Recruiting Clinical Trials

NCT06241521
Recruiting
Myasthenia Gravis Registry in China
Enrollment
1,500 pts
Location
China
Sponsor
Huashan Hospital
View Trial →
NCT07673744 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Enrollment
120 pts
Location
United States
Sponsor
TG Therapeutics, Inc.
View Trial →
NCT06193889 Phase 2, Phase 3
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Enrollment
66 pts
Location
United States, Austr...
Sponsor
Kyverna Therapeutics
View Trial →
NCT07146425
Recruiting
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
Enrollment
180 pts
Location
China
Sponsor
Huashan Hospital
View Trial →
NCT04837625
Recruiting
Study of Myasthenic Crisis in China
Enrollment
300 pts
Location
China
Sponsor
Huashan Hospital
View Trial →
NCT06866652
Recruiting
Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
Enrollment
50 pts
Location
France
Sponsor
Institut de Myologie, France
View Trial →

Related Conditions

generalized myasthenia gravis (1) myasthenic crisis (1) dyspnea (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology